

CORRECTION

Open Access



Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Abolghasem Allahyari¹, Ali Ehsanpour², Behrouz Najafi³, Nafseh Ansarinejad⁴, Valiollah Mehrzad⁵, Behjat Kalantari⁶, Jahangir Raafat⁷, Mojtaba Ghadiany⁸, Farhad Shahi⁹, Behrooz Gharib¹⁰, Vahid Moazed¹¹, Adnan Khosravi¹², Mir Hossein Mirpour¹³, Sina Salari¹⁴, Seyedmohammadreza Mortazavizadeh¹⁵, Amirabbas Nekoyi¹⁶, Mohsen Khani¹⁷, Alireza Sadeghi¹⁸, Sirius Gharib¹⁹, Alireza Bary²⁰, Mehrzad Mirzania²¹, Shirin Haghighat²², Seyed Mohsen Razavi²³, Seyed Amir Hossein Emami²⁴, Mehran Hosseinzadeh²⁵, Mahdi Mirbolouk²⁶, Sanambar Sadighi²⁷, Abdolali Shahrabi²⁸, Ali Esfahani²⁹, Masoumeh Gity³⁰, Nassim Anjidani³¹, Hamidreza Kaf³¹ and Safa Najaf^{32*}

Correction: BMC Cancer 22, 960 (2022)
<https://doi.org/10.1186/s12885-022-09895-5>

Following publication of the original article [1], the authors identified that Behrouz Najafi was omitted as the third author in the author group. The author group in this correction article has been updated and the original article [1] has been corrected.

Author details

¹Hematology Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ²Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ³Hematology and Oncology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science, Razi

The original article can be found online at <https://doi.org/10.1186/s12885-022-09895-5>.

*Correspondence: Safa3n@yahoo.com

³²Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Full list of author information is available at the end of the article

Hospital, Rasht, Iran. ⁴Department of Hematology & Oncology, Iran University of Medical Sciences, Tehran, Iran. ⁵Hematology and Oncology Department, Isfahan Medical School, Isfahan, Iran. ⁶Hematology & Oncology, Department of Internal Medicine, School of Medicine, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran. ⁷Mehrad Hospital, Tehran, Iran. ⁸Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁹Department of Hematology and Medical Oncology, Breast Disease Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, TUMS, Tehran, Iran. ¹⁰Department of Medical Oncology & Hematology, Naft Hospital, Tehran, Iran. ¹¹Hematology & Oncology Kerman University of Medical Sciences, Kerman, Iran. ¹²Hematology & Oncology, Department of Adult Hematology & Oncology, School of Medicine, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Dr. Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹³Medical Oncology Guilan University of Medical Sciences, Razi Hospital, Fuman, Iran. ¹⁴Medical Oncology, Hematology Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹⁵Hematology/Oncology Yazd Azad University, Yazd, Iran. ¹⁶Department of Hematology and Medical Oncology, Seyyed-al-shohada Hospital, Esfahan University of Medical Sciences, Tehran, Iran. ¹⁷Medicine Saba Oncology Clinic, Isfahan, Iran. ¹⁸Department of Hematology-Oncology, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁹Hematology, Oncology Department of Internal Medicine, Guilan University of Medical Sciences, Guilan, Iran. ²⁰Department of Hematology & Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. ²¹Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Imam Khomeini Hospital



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Complex, Tehran University of Medical Sciences, Tehran, Iran.²²Hematology Research Center, Hematology and Medical Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran.²³Iran Medical Science University, Tehran, Iran.²⁴Medical Oncology, Cancer Institute, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.²⁵Hematology, Oncology Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.²⁶Hazrat Rasol Hospital Rasht, Gilan, Iran.²⁷Internal Medicine Group TUMS Faculty of Cancer Institute of Iran, Tehran, Iran.²⁸Bouali Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.²⁹Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.³⁰Advanced Diagnostic and Interventional Radiology Research Center, Breast Disease Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.³¹Medical Department, Orchid Pharmed Company, Tehran, Iran.³²Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Published online: 22 December 2022

Reference

1. Allahyari A, Ehsanpour A, Najafi B, et al. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalence clinical trial. *BMC Cancer*. 2022;22:960. <https://doi.org/10.1186/s12885-022-09895-5>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

